FRA:J8J (China)
Â
Ordinary Shares - Class H
€
1.06
+0.030 (+2.91%)
Aug 20
Business Description
TransThera Sciences (Nanjing) Inc
ISIN : CNE100006T02
Share Class Description:
FRA:J8J: Ordinary Shares - Class HTotal Employee Number:
123Compare
Compare
Traded in other countries / regions
02617.Hong KongJ8J.Germany IPO Date
2026-01-12Description
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its core Product Tinengotinib is a multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 297.23 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.08 | |||||
9-Day RSI | 39.07 | |||||
14-Day RSI | 33.13 | |||||
3-1 Month Momentum % | -78.16 | |||||
6-1 Month Momentum % | -84.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.87 | |||||
Quick Ratio | 3.87 | |||||
Cash Ratio | 3.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -4.48 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -58.94 | |||||
ROA % | -48.05 | |||||
ROIC % | -526.3 | |||||
ROC (Joel Greenblatt) % | -1823.23 | |||||
ROCE % | -58.85 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 8.9 | |||||
Price-to-Tangible-Book | 8.83 | |||||
EV-to-EBIT | -11.25 | |||||
EV-to-EBITDA | -11.44 | |||||
EV-to-FCF | -13.12 | |||||
| Price-to-Net-Current-Asset-Value | 9.64 | |||||
| Price-to-Net-Cash | 10.6 | |||||
Earnings Yield (Greenblatt) % | -8.89 | |||||
FCF Yield % | -6.64 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TransThera Sciences (Nanjing) Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.092 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 33.13 | ||
| 14-Day ATR (€) | 0.097358 | ||
| 20-Day SMA (€) | 1.089 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 1 - 12.2 | ||
| Shares Outstanding (Mil) | 407.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TransThera Sciences (Nanjing) Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TransThera Sciences (Nanjing) Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
TransThera Sciences (Nanjing) Inc Frequently Asked Questions
What is TransThera Sciences (Nanjing) Inc(FRA:J8J)'s stock price today?
The current price of FRA:J8J is €1.06. The 52 week high of FRA:J8J is €12.20 and 52 week low is €1.00.
When is next earnings date of TransThera Sciences (Nanjing) Inc(FRA:J8J)?
The next earnings date of TransThera Sciences (Nanjing) Inc(FRA:J8J) is .
Does TransThera Sciences (Nanjing) Inc(FRA:J8J) pay dividends? If so, how much?
TransThera Sciences (Nanjing) Inc(FRA:J8J) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on TransThera Sciences (Nanjing) Inc
No articles.